PRS 080

Drug Profile

PRS 080

Alternative Names: PRS080

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Antianaemics; Lipocalins
  • Mechanism of Action Hepcidin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Iron deficiency anaemia

Most Recent Events

  • 27 Feb 2017 Pieris grants ASKA Pharmaceutical option to license PRS 080 in Japan, South Korea and other Asian countries excluding China
  • 30 Apr 2016 Pieris Pharmaceuticals initiates enrolment in a phase Ib trial for Iron-deficiency anaemia in Germany (NCT02754167)
  • 01 Jan 2016 Phase-I/II clinical trials for Iron-deficiency anaemia (in patients with Renal failure) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top